Interim Statement 9M 2026

On November 5, 2026 Evotec reported interim statement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, Evotec, NOV 5, 2026, View Source [SID1234675053])

Lantheus Reports Third Quarter 2026 Financial Results

On November 5, 2026 Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, reported financial results for its third quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, and as previously announced, Lantheus entered into a definitive agreement on August 3, 2026 to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares of Lantheus for $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights ("CVRs") providing for up to $12.00 per share in potential additional cash payments, subject to achievement of specified commercial milestones for Lantheus’ products through 2030. The transaction represents a total per share consideration of up to $114.50 and a total transaction value of up to approximately $8.0 billion. Together, Curium and Lantheus are positioned to create a radiopharmaceutical company spanning diagnostics and therapeutics, with the infrastructure and capabilities to serve patients in more than 70 countries. The Board of Directors of Lantheus has unanimously approved the transaction. Additional information regarding the transaction is available in the Company’s Current Report on Form 8-K filed with the SEC on August 4, 2026.

In connection with the pending transaction, Lantheus is suspending its previously issued full year 2026 financial guidance and will not be hosting a conference call in connection with its third quarter 2026 results.

Summary Financial Results

Three Months Ended
September 30,
(in millions, except per share data – unaudited) 2026 2025 % Change
Worldwide revenue $ 389.9 $ 384.0 1.5 %
GAAP net income $ 22.4 $ 27.8 (19.4 %)
GAAP fully diluted earnings per share $ 0.33 $ 0.41 (19.5 %)
Adjusted net income (non-GAAP) $ 115.1 $ 85.7 34.3 %
Adjusted fully diluted earnings per share (non-GAAP) $ 1.68 $ 1.27 32.3 %

Third Quarter 2026

Worldwide revenue increased 1.5% to $389.9 million compared to the same period in 2025.
Sales of PYLARIFY were $238.9 million, a decrease of 0.7%.
Sales of Neuraceq were $45.6 million, an increase of 123.0%.
Sales of DEFINITY were $85.7 million, an increase of 4.8%.
Operating income decreased 26.2% to $32.2 million. Adjusted operating income (non-GAAP) increased 28.1% to $153.2 million.
Fully diluted earnings per share decreased 19.5% to $0.33, compared to fully diluted earnings per share of $0.41 in the prior year period. Adjusted fully diluted earnings per share (non-GAAP) increased 32.3% to $1.68, compared to $1.27 in the prior year period.
Net cash provided by operating activities and free cash flow were $102.0 million and $99.9 million, respectively.

Balance Sheet

At September 30, 2026, the Company’s cash and cash equivalents were $683.6 million, compared to $359.1 million at December 31, 2025.
The Company currently has access to up to $750.0 million from a revolving line of credit.

Recent Business Highlights

Received CMS Transitional Pass-Through payment status and a permanent HCPCS code, each effective October 1, 2026, for PYLARIFY TruVu (piflufolastat F18), supporting the Company’s previously announced phased geographic commercial launch.
Received FDA approval for TAUKLARIFY (florquinitau F-18 injection), an F-18-labeled tau PET imaging agent for the evaluation of adults with cognitive impairment being assessed for Alzheimer’s disease. The Company intends to continue supporting Alzheimer’s disease therapeutic programs through its Pharma Solutions business while assessing the appropriate path toward broader commercial availability.
Received final FDA approval for BRAVNETSA (lutetium Lu 177 dotatate), the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to LUTATHERA for the treatment of adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors; the Company is preparing for a thoughtful commercial launch to support reliable supply and broad patient access.
Dosed the first patient in the SPARROW study, a Phase 2/3 registrational trial evaluating LNTH-2401, the Company’s investigational GRPR-targeted PET imaging agent for prostate cancer; the Phase 3 portion is expected to enroll approximately 400 participants and evaluate diagnostic performance, safety and tolerability.

(Press release, Curium Pharma, NOV 5, 2026, View Source [SID1234674304])

Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as it Advances PH-762 Toward Phase 2b Study Initiation

On November 5, 2026 Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics using its proprietary INTASYL gene-silencing technology to eliminate cancer, reported financial results for the quarter ended September 30, 2026, and provided a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have successfully executed on critical development objectives to advance the PH-762 program toward Phase 2b study initiation," said Robert J. Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals. "Commercial-scale drug substance manufacturing was completed and shipped to our drug product manufacturer in preparation for making clinical trial supply material. We have submitted detailed information to FDA providing final analysis of our Phase 1b clinical trial and the fundamentals of our intended upcoming Phase 2b study."

PH-762 Development Update

PH-762 was evaluated in a U.S. multicenter Phase 1b dose-escalation clinical trial assessing intratumoral administration in patients with cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma. The study (NCT 06014086) was designed to evaluate the safety and tolerability of neoadjuvant treatment with PH-762, assess tumor response, and identify a dose or dose range for further clinical development. The study enrolled 22 patients, consisting of 20 patients with cutaneous squamous cell carcinoma, one patient with melanoma, and one patient with Merkel cell carcinoma.

The clinical trial was completed in June 2026, and the final clinical study report was submitted to FDA with a meeting request and briefing document outlining the nonclinical and clinical pharmacology programs, scientific rationale for continued development, completed Phase 1b results, and details of the planned Phase 2b neoadjuvant study in cSCC. The submission seeks FDA feedback on the proposed development strategy and next steps, with a response expected from the FDA by the end of November 2026.

The Company also announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance (active pharmaceutical ingredient), representing an important CMC (chemistry, manufacturing and controls) milestone that supports the planned Phase 2b clinical program, which is expected to be initiated in the first quarter of 2027.

Scientific and Corporate Activities

During the quarter, the Company presented PH-762 Phase 1b clinical trial data at scientific and investor conferences and roadshows. These included the Life Sciences Future Conference, King of Prussia, PA, H.C. Wainwright Conference, NYC, NIBA 153rd Conference, Fort Lauderdale, FL, Life Sciences Virtual Investor Conference, and Renmark Financial Virtual Non-Deal Roadshows.

The Company further strengthened its intellectual property position through multiple patent-related achievements during the quarter. Phio’s patent portfolio currently includes 56 issued patents and 34 pending applications worldwide, providing broad protection for its INTASYL self-delivering RNAi therapeutic platform and product candidates through at least 2038, with additional pending applications extending potential protection into 2044.

Financial Results

Cash Position

As of September 30, 2026, we had cash and cash equivalents of $10.6 million as compared with $21.0 million at December 31, 2025. The Company continues to focus its resources on advancing PH-762 while prudently managing general and administrative expenses.

Research and Development Expenses

Research and development expenses for the three months ended September 30, 2026 were $3.0 million, an increase of $1.9 million or 159%, compared with the three months ended September 30, 2025. The increase was primarily driven by a $1.5 million increase in nonclinical toxicology study costs, drug substance costs and clinical supplies costs as compared to the clinical study costs that occurred during the prior year period, and a $0.3 million increase in other development related costs.

Research and development expenses for the nine months ended September 30, 2026 were $8.9 million, an increase of $5.8 million or 180% as compared with the nine months ended September 30, 2025. The increase in research and development expenses was primarily driven by a $4.5 million increase in nonclinical toxicology study costs, drug substance costs and clinical supplies costs, all of which were associated with advancing the PH-762 program. In addition, research and development expenses increased by approximately $0.3 million related to employee headcount costs, $0.6 million related to outside services and consultants and $0.2 million related to patent activity.

Management believes that research and development expenses will continue to increase as we advance our PH-762 program.

General and Administrative Expenses

General and administrative expenses for the three months ended September 30, 2026 were $1.2 million, a decrease of $100 thousand or 9%, compared with the three months ended September 30, 2025. This decrease was primarily driven by a reduction in outsourced consulting services.

General and administrative expenses for the nine months ended September 30, 2026 increased 6% or $200 thousand as compared with the nine months ended September 30, 2025. The increase was primarily driven by a $1.2 million increase in employee costs, of which $0.7 million related to increased stock-based compensation expenses. This increase was partially offset by a $1.1 million decrease in outside services and consultant expenses as compared to the prior year period.

Net Loss

Net loss was $4.2 million for the three months ended September 30, 2026 as compared with $2.4 million for the three months ended September 30, 2025. The increase in net loss was attributable to higher research and development expenses associated with advancing the PH-762 program.

(Press release, Phio Pharmaceuticals, NOV 5, 2026, View Source [SID1234674320])

Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

On November 5, 2026 Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, reported financial results for the third quarter ended September 30, 2026, and highlighted recent business progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"During the third quarter, we made significant progress with VS-7375, our potential best-in-class oral KRAS G12D (ON/OFF) inhibitor. Our first U.S. clinical data established a new monotherapy efficacy benchmark in metastatic pancreatic cancer and showed early but encouraging antitumor activity in colorectal and lung cancers, all driven by KRAS G12D, while continuing to demonstrate a manageable safety and tolerability profile without many of the on-target toxicities associated with pan-RAS approaches. Following alignment with the FDA, we plan to open our Phase 3 TARGET-D 301 trial in first-line KRAS G12D-driven metastatic pancreatic cancer by the end of the year. We also expect to engage with the FDA before year-end on Phase 3 trial designs in colorectal and lung cancers. We believe VS-7375 has transformative potential for patients with KRAS G12D-driven cancers and remain focused on advancing our pivotal programs in 2027," said Dan Paterson, president and chief executive officer at Verastem Oncology. "Demand for AVMAPKI FAKZYNJA CO-PACK remained steady during the third quarter, with strong refill rates generating $24.0 million in net product revenue. We remain confident in the long-term opportunity and anticipate a more gradual sales ramp given the episodic nature of treatment persistence in this rare disease. The FDA has accepted our NDA for the new blister pack, to further support patient convenience and adherence, and granted priority review with a decision anticipated by February 2027."

Third Quarter 2026 and Recent Updates

AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets)

AVMAPKI FAKZYNJA CO-PACK generated net product revenue of $24.0 million for the third quarter of 2026. Strong refill growth drove revenue, partially offset by fewer new patient starts due to seasonal headwinds, the implementation of recent commercial team changes, and evolving patterns of off-label use.
On October 14, the Company communicated that the U.S. Food and Drug Administration (FDA) had accepted the New Drug Application (NDA) for the AVMAPKI FAKZYNJA CO-PACK Blister Pack, granting it Priority Review with an FDA decision by February 7, 2027. The Company believes the new package presentation is an important step in further supporting patient convenience and adherence.
In October, new data from the Company’s Phase 2 RAMP 201 clinical trial of avutometinib plus defactinib in patients with recurrent low-grade serous ovarian cancer (LGSOC) were presented at the International Gynecologic Cancer Society (IGCS) 2026 Annual Global Meeting. The RAMP 201 molecular profiling analysis showed clinically meaningful activity in KRAS wild-type recurrent LGSOC, including overall response rates (ORR) of 22% in patients with NRAS- or BRAF-mutated tumors and 18% in patients with KRAS/NRAS/BRAF triple wild-type tumors. Additionally, an external control arm analysis of RAMP 201 showed higher weighted ORR and statistically significant improvements in progression free survival (PFS) versus conventional care in both KRAS-mutated and KRAS wild-type subgroups.
In September, the Company announced that two-year results evaluating the efficacy and safety of AVMAPKI FAKZYNJA CO-PACK in women with recurrent LGSOC from the RAMP 201 study were published online and in the October print issue of Gynecologic Oncology, the official journal of the Society of Gynecologic Oncology (SGO). In the updated analysis, with ongoing patients presenting a median follow-up of 24.9 months, efficacy measures, including median duration of response and median PFS, and safety, are consistent with the primary analysis, which was conducted more than 13 months prior.
In July, updated data from the RAMP 201 Japan study were presented at the Annual Meeting of the Japanese Society of Gynecologic Oncology and demonstrated consistent pharmacokinetics (PK), efficacy, and safety profile with the RAMP 201 study.
Expected Key Milestones:

FDA decision on NDA submitted for the AVMAPKI FAKZYNJA CO-PACK Blister Pack by February 7, 2027.
Report a topline readout of the primary endpoint in the RAMP 301 trial of avutometinib plus defactinib in patients with recurrent LGSOC in mid-2027.
Continue to pursue regulatory paths for potential expansion of recurrent LGSOC into Europe and Japan.
VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor in Advanced Solid Tumors

In October, the Company reported initial efficacy and updated safety and tolerability data for VS-7375 in pancreatic, lung, and colorectal cancers from the ongoing Phase 1/2 TARGET-D 101 clinical development program.
In metastatic pancreatic ductal adenocarcinoma (mPDAC), VS-7375 900 mg once daily (QD) monotherapy achieved a confirmed objective response rate (cORR) of 50% (4/8) in the second line (2L) setting, a 41% cORR (9/22) in 2L or later (2L+) setting, including two complete responses, one confirmed and one unconfirmed (treatment ongoing), and 36% cORR (5/14) in the third and fourth line (3L/4L) settings. The disease control rate (DCR) was 86%, and the six-month landmark PFS rate was 67%.
VS-7375 600 mg QD monotherapy achieved a cORR of 43% (10/23) in 2L+ non-small cell lung cancer (NSCLC). In preliminary first line (1L) data, VS-7375 600 mg QD in combination with standard-of-care (SoC) carboplatin, pemetrexed, and pembrolizumab achieved an ORR of 75% (6/8) in 1L KRAS G12D adenocarcinoma of the lung. The 900 mg QD dose level is currently being evaluated in the TARGET-D 202 Phase 2 registration-directed advanced NSCLC trial.
In early data in 3L+ metastatic colorectal cancer (mCRC), VS-7375 900 mg in combination with anti-EGFR therapy achieved an ORR of 33% (2/6; one confirmed and one unconfirmed response).
Across TARGET-D 101 monotherapy and combination cohorts, VS-7375 demonstrated a favorable and manageable safety profile at both the 600 mg (n=73) and 900 mg dose levels (n=48), with no clinically significant cumulative toxicities observed. At 900 mg once daily, the adverse event-related discontinuation rate was 2%, median relative dose intensity was 97%, and treatment-related adverse events (TRAEs) were primarily low-grade gastrointestinal events; Grade 3 TRAEs occurred in 10% of patients. Combination regimens with SoC therapies were generally consistent with the safety profiles of the individual agents, with no new or meaningful overlapping toxicities observed.
In October, the Company also shared that it had reached alignment with the FDA on the design of TARGET-D 301, a three-arm Phase 3 pivotal trial in 1L mPDAC evaluating VS-7375 900 mg in combination with anti-EGFR therapy (chemotherapy-free option) and VS-7375 900 mg in combination with gemcitabine and nab-paclitaxel versus investigator’s choice of SoC chemotherapy.
In July, the Company announced the first patients were dosed in both the TARGET-D 203 CRC and the TARGET-D 202 NSCLC clinical trials. Together with the previously announced dosing of the first patient in the TARGET-D 201 mPDAC trial in June, enrollment is ongoing across all three TARGET-D registration-directed Phase 2 studies.
Expected Key Milestones:

Plan to meet with the FDA before the end of the year to review Phase 3 pivotal trial designs in 1L mCRC (TARGET-D 303) and 1L advanced NSCLC (TARGET-D 302).
Expect to complete enrollment in the TARGET-D 201 (PDAC) and TARGET-D 203 (CRC) Phase 2 trials by the end of 2026; TARGET-D 202 (NSCLC) expected in Q2 2027.
Plan to report mature data from the TARGET-D 101 mCRC cohort evaluating VS-7375 900 mg in combination with anti-EGFR therapy in Q1 2027 to allow for additional patient follow-up.
Plan to report initial data from the TARGET-D 101 mPDAC cohort evaluating VS-7375 600 mg plus cetuximab in early 2027, with the data intended for presentation at a medical meeting.
Plan to open the TARGET-D 301 1L mPDAC trial by year-end 2026. Plan to enroll the first patient in the CRC and NSCLC Phase 3 pivotal trials in the first half of 2027.
Expect to report initial data from the 1L mPDAC combination with gemcitabine/Nab-paclitaxel in early Q2 2027, with the data intended for presentation at a medical meeting.
Plan to report initial Phase 2 data from TARGET-D 201 in 2L PDAC in Q2 2027; expect to report initial data from TARGET-D 202 in 2L NSCLC and TARGET-D 203 in 2L CRC in 2H 2027. Data from all three trials are intended for presentation at a medical meeting.
Corporate Updates

In October, Verastem announced the appointment of Michael P. Bailey as President and Chief Executive Officer (CEO), effective January 1, 2027. The CEO transition follows the planned retirement of Daniel Paterson, who will step down as President and CEO and continue to serve on the Company’s Board of Directors and as an advisor to the Company.
In October, Verastem strengthened its balance sheet by raising gross proceeds of approximately $250 million in a public offering of 30,937,500 shares of its common stock and pre-funded warrants to purchase 312,503 shares of its common stock.
Verastem selected a second program to advance under its research collaboration with GenFleet; a previously selected third program has been discontinued due to technical futility, and the targets for both programs remain undisclosed. Separately, the companies amended their August 2023 agreement. Under the new terms Verastem will lead Investigational New Drug-enabling studies and clinical development outside of China for the second program while allowing GenFleet the option to retain China rights based on Phase 1 safety data from the ex-China study. The financial terms of the original agreement have been amended with Verastem having no additional near-term payment for gaining rights to the second program, with future success-based milestone payments tied to achieving clinical regulatory, and sales milestones.
In September, Verastem received the 2026 Industry Innovation and Rare Impact Award from the National Organization for Rare Disorders (NORD) and was listed by Fierce Healthcare as a 2026 Fierce 50 honoree in the Breakthrough category, both awards recognizing the innovation behind the first FDA-approved treatment specifically for adults with KRAS-mutated recurrent LGSOC.
Third Quarter 2026 Financial Results

Verastem Oncology ended the third quarter of 2026 with cash, cash equivalents, and investments of $172.8 million, inclusive of the $50.0 million non-dilutive royalty financing arrangement that closed on August 28, 2026. On a pro forma basis, taking into account the $250.0 million of gross proceeds raised in a follow-on offering in October, cash and cash equivalents were $422.8 million as of September 30, 2026. Based on Verastem’s cash position, gross proceeds from the October financing, and expected revenues from AVMAPKI FAKZYNJA CO-PACK sales, Verastem believes it has the capital to fund its operating plan into the first half of 2028, including the initiation of three pivotal Phase 3 studies in PDAC, CRC, and NSCLC.

Net product revenue for the three months ended September 30, 2026 (2026 Quarter) was $24.0 million, compared to $11.2 million in net product revenue recognized for the three months ended September 30, 2025 (2025 Quarter). Total operating expenses for the 2026 Quarter were $99.2 million, compared to $52.0 million for the 2025 Quarter. Cost of sales was $3.9 million for the 2026 Quarter, compared to $2.0 million for the 2025 Quarter.

Research & development expenses for the 2026 Quarter were $68.8 million, compared to $29.0 million for the 2025 Quarter. The increase of $39.8 million, or 137%, was primarily due to increased costs for investigator fees, drug substance and drug product manufacturing costs, contract research organization costs, and personnel costs, including non-cash stock-based compensation.

Selling, general & administrative expenses for the 2026 Quarter were $26.5 million, compared to $21.0 million for the 2025 Quarter. The increase of $5.5 million, or 26%, was primarily due to higher costs for personnel, including non-cash stock-based compensation, and commercial operations.

Net loss (GAAP basis) for the 2026 Quarter was $74.7 million, or $0.74 per share (basic and diluted), compared to $98.5 million, or $1.35 per share (basic and diluted) for the 2025 Quarter.

Non-GAAP adjusted net loss for the 2026 Quarter was $72.8 million, or $0.72 per share (basic), compared to non-GAAP adjusted net loss of $39.1 million, or $0.53 per share (basic), for the 2025 Quarter. Please refer to the GAAP to non-GAAP Reconciliation attached to this press release.

Conference Call and Webcast

Verastem will host a conference call and webcast today at 4:30 p.m. ET to review the third quarter 2026 financial results and recent business updates. To access the live audio webcast of the call, along with accompanying slides, please visit the "Events & Presentations" page in the Investor section of the Company’s website, View Source A replay of the webcast will be archived and available following the event.

(Press release, Verastem, NOV 5, 2026, View Source [SID1234674348])

Flatiron Health Announces Research at ISPOR Europe 2026 Advancing Global Oncology Evidence for Health Technology Assessment

On November 5, 2026 Flatiron Health reported seven research abstracts to be presented at ISPOR—The Professional Society for Health Economics and Outcomes Research Europe 2026 conference, taking place November 8–11 in Vienna, Austria. The research examines how real-world evidence can support health technology assessment (HTA), how oncology findings may translate across countries, and how transparent validation can support the use of AI-derived data in research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Flatiron will also host a speaking session on scaling AI-curated oncology data across countries, featuring clinical and scientific experts discussing how to maintain data accuracy, consistency, and clinical relevance as datasets expand across markets and disease areas.

"Answering whether a cancer treatment works is only part of the challenge. Researchers and health technology assessment bodies also need to understand how that evidence applies to patients in different healthcare systems," said Nathan Hubbard, Chief Executive Officer, Flatiron Health. "Our research at ISPOR Europe examines what it takes to make those judgments with confidence, from understanding differences in treatment patterns to validating the quality of AI-derived data. This work can help strengthen the evidence that informs access to cancer treatments."

Flatiron combines multinational oncology data from the US, UK, Germany, and Japan with clinical expertise and analytical methods to address questions facing researchers, payers, and regulators. This year’s studies examine both the opportunities and practical considerations involved in generating evidence across healthcare systems, including population comparability, subsequent treatment choices, and differences in routine monitoring.

Research highlights include:

Evaluating when evidence can inform decisions across countries. Three studies examine the transportability of oncology evidence, including a structured approach to reviewing cross-country studies, benchmarking methods for comparing survival estimates, and a comparison of US and Finnish metastatic non–small cell lung cancer (NSCLC) cohorts. Together, the studies explore how researchers can assess whether international evidence is appropriate for local HTA questions.
Understanding how subsequent care affects survival analyses. An advanced NSCLC analysis examines how second-line treatment patterns can influence estimates of first-line treatment effects on real-world overall survival. The methods offer a way to distinguish the effects of initial therapy from differences in the treatment patients receive next.
Assessing AI-derived data quality and cross-country safety measurement. A UK prostate cancer study extends Flatiron’s VALID framework to evaluate data extracted using large language models. A separate study examines how laboratory monitoring practices in the UK, Germany, and Japan may influence detection of liver toxicity among patients receiving CDK4/6 inhibitors for advanced breast cancer.
Examining variation in metastatic prostate cancer treatment. A US study describes differences in treatment selection and androgen receptor pathway inhibitor reuse across racial, ethnic, and area-level socioeconomic groups, highlighting questions for further research into access and clinical decision-making.
At booth #1018, attendees can explore Flatiron’s global Panoramic datasets through live demonstrations of Flatiron Telescope, its AI-powered oncology intelligence platform.

Schedule a meeting with Flatiron Health at ISPOR Europe 2026 and follow Flatiron Health on LinkedIn for conference updates.

Featured Speaking Session

Setting the global standard: What it takes to scale AI-curated oncology data across countries

Tuesday, November 10 | 15:15–15:45 | Exhibit Hall

Arun Sujenthiran, MD, Clinical Lead and Senior Medical Director, International, and Qianyi Zhang, MS, Director, Research Sciences, will discuss Flatiron’s approach to transparent data validation and its application across US and international oncology datasets.

Abstracts and Poster Presentations

Key Considerations for Synthesizing Cross-Country Oncology RWE Transportability Studies

This study identifies five recurring methodological dimensions across oncology transportability studies and proposes a practical checklist to help HTA bodies and regulators interpret international real-world evidence.

Poster Session 1 | SA8
Monday, November 9 | 10:30–13:30
Discussion period: 12:30–13:30

Benchmarking as a Tool for Assessing Cross-Country Comparability of Survival Evidence for HTA

Using exploratory case studies in metastatic NSCLC and multiple myeloma, this analysis examines how comparisons of predicted and reference survival estimates may help researchers assess the suitability of international evidence for HTA.

Poster Session 1 | HTA28
Monday, November 9 | 10:30–13:30
Discussion period: 12:30–13:30

Comparison of Patient Characteristics and First-Line Treatment Patterns in Metastatic NSCLC: US and Finland Cohorts to Inform Overall Survival Transportability Analyses

This study compares patient characteristics and first-line treatment patterns in US and Finnish cohorts to inform future analyses of whether survival findings can be applied across the two settings.

Poster Session 2 | SA30
Monday, November 9 | 16:00–19:00
Discussion period: 18:00–19:00

Controlling for What Comes Next: Estimating Generalized Direct Effects of First-line Therapy on Real-world Overall Survival Using Counterfactual Second-line Distributions in Advanced Non-small Cell Lung Cancer

This analysis explores a method for estimating first-line treatment effects on survival under alternative second-line treatment scenarios, helping researchers account for differences in subsequent care.

Poster Session 4 | MSR200
Tuesday, November 10 | 16:00–19:00
Discussion period: 18:00–19:00

Extending the Validation of Accuracy for Large Language Model (LLM)–/Machine Learning (ML)–Extracted Information and Data (VALID) Framework Globally: Quality Assessment of LLM-Derived Prostate Cancer Real-World Data in the UK

Applying the VALID framework to a UK prostate cancer dataset, this study evaluates LLM-derived data through variable-level assessments, clinical plausibility checks, and replication analyses.

Poster Session 5 | MSR263
Wednesday, November 11 | 09:00–11:30
Discussion period: 09:00–10:00

Real-World First-Line Treatment (tx) Patterns in Androgen Receptor Pathway Inhibitor (ARPI)-Experienced Metastatic Castration-Resistant Prostate Cancer (mCRPC) by Race/Ethnicity and Area-Level Socioeconomic Status (SES) in the US

This study describes variation in first-line treatment selection and ARPI reuse across racial, ethnic, and area-level socioeconomic groups among US patients with ARPI-experienced metastatic castration-resistant prostate cancer.

Poster Session 1 | HSD15
Monday, November 9 | 10:30–13:30
Discussion period: 12:30–13:30

Cross-Country Differences in Real-World Laboratory Monitoring Intensity and Hepatotoxicity Adverse Event Detection Among Initiators of CDK4/6 Inhibitors for Advanced Breast Cancer

This study examines how differences in laboratory monitoring across the UK, Germany, and Japan may influence observed liver toxicity rates and the interpretation of cross-country safety evidence.

Poster Session 5 | RWD173
Wednesday, November 11 | 09:00–11:30
Discussion period: 09:00–10:00

(Press release, Flatiron Health, NOV 5, 2026, View Source [SID1234674364])